
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is a preclinical biotech company that leverages AI for precision antibody development, but its lack of revenue and need for future funds increases risk. The company faces competition from more established firms with larger resources, and its patents may not fully protect its products. iBio is developing a bispecific antibody targeting TGF-β ligands for a potential treatment in disease progression of PH-HFpEF, but its products still have clinical and regulatory risks to be addressed.
Bears say
iBio is primarily a preclinical stage biotechnology company that is developing precision antibodies using AI-guided epitope-steering and monoclonal antibody optimization technology. While the company has shown promising results in preclinical studies with its products IBIO-600 and IBIO-610, it faces significant competition in the intensely competitive biotechnology and pharmaceutical industries. Additionally, the company is currently in a development stage, meaning it does not have any products generating revenue and will likely need to raise additional funds in the future, which could be challenging in the current financial environment. As a result, there is no guarantee that the company's products will ultimately receive market approval, and investors should be aware of the potential risks associated with investing in iBio.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares